What’s New?
latest
news
Please note that this website contains forward-looking statements that should not be taken as guarantees of future performance or relied upon as predictors of outcomes.
Kynos Therapeutics announces a first-in-human Phase I study of its novel small molecule KMO inhibitor, KNS366, is underway
18.05.2023
Kynos Therapeutics announces the strengthening of its Board with the appointment of experienced biotech entrepreneur Jean Combalbert as independent Chair
19.01.2023
Kynos Therapeutics announces the expansion of its leadership team with the appointment of Jonathan Savidge as CEO
11.11.2022
Kynos builds out senior management team with appointment of Dr Alison Strutt, a seasoned biotech and ex-GSK executive, as CFO
23.06.2022
Kynos Therapeutics Emerges from Stealth with £9 Million Financing and Phase 1-ready KMO Inhibitor
07.04.2022
address OPERATIONAL HEADQUARTERS
Kynos Therapeutics Ltd.
Enterprise Hub 2.14
Murchison House
King's Buildings
10 Max Born Crescent
Edinburgh EH9 3BF
United Kingdom
phone
email
get-in-touch
To contact Us ,
please use
the form
tnx-msg